IP transactions partner Geoffrey Lin spoke to the Pink Sheet about the BIOSECURE Act, a bill that would make it more difficult for Chinese biotech companies to do business in the U.S., for a March 14 article.
Geoffrey addressed the effects the bill would have on the biopharmaceutical industry. WuXi App Tech, one of the companies covered in the legislation, “provides billions of U.S. dollars of services and supplies to the US market each year,” he told the PinkSheet. Limiting WuXi’s ability to operate could affect both manufacturing and the conduct of research and trials, Geoffrey added.
“Moving to another source of clinical or commercial supply could take up to two years in certain instances,” Geoffrey said, although he noted that the situation would be case-specific. “Due to the volume of business WuXi supports, in many cases, it likely will be challenging to find and efficiently transition to an alternative partner without significant loss of time.”
The article also quotes a Ropes & Gray alert about the BIOSECURE Act.
Click here to read the article in full (subscription required).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.